Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study)

Of 60,083 patients in the incident EC cohort (median follow-up 2.0 years; median age 70 years), 23,060 met criteria for the initial metastatic and/or recurrent EC cohort (median follow-up 1.2 years; median age 71 years). Sociodemographic characteristics and comorbidities were similar between cohorts. In first line, 45.3% of the incident EC cohort and 7.4% of the metastatic/recurrent cohort underwent surgery alone, while 5.2% and 31.2%, respectively, received chemotherapy. Chemotherapy alone was the most frequent intervention in both cohorts. Median OS and TTNTD from index date were both not reached in the incident EC cohort, and 2.3 and 1.1 years, respectively, in the metastatic/recurrent EC cohort. At 2 years of follow-up, 21% of patients in the incident EC cohort and 37% in the metastatic/recurrent EC cohort had switched to second-line treatment.